Cargando…

Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis

BACKGROUND: Despite the existence of effective drug treatments, tuberculosis (TB) causes 2 million deaths annually worldwide. Effective treatment is complicated by multidrug-resistant TB (MDR TB) strains that respond only to second-line drugs. We projected the health benefits and cost-effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Resch, Stephen C, Salomon, Joshua A, Murray, Megan, Weinstein, Milton C
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1483913/ https://www.ncbi.nlm.nih.gov/pubmed/16796403 http://dx.doi.org/10.1371/journal.pmed.0030241

Ejemplares similares

1881. Costs of Treating Multidrug Resistant Tuberculosis in California, 2022
por: Katrak, Shereen, et al.
Publicado: (2023)

Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the Philippines
por: Tupasi, Thelma E, et al.
Publicado: (2006)

The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China
por: Weerasuriya, Chathika K, et al.
Publicado: (2021)

Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia
por: Alemayehu, Senait, et al.
Publicado: (2020)

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1
por: Linas, Benjamin P., et al.
Publicado: (2016)

Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru
por: Cohen, Ted, et al.
Publicado: (2011)

Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
por: Menzies, Nicolas A., et al.
Publicado: (2012)

Acquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social Determinants
por: Odone, Anna, et al.
Publicado: (2016)

The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia
por: Miller, Thaddeus L, et al.
Publicado: (2013)

Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China
por: Weerasuriya, Chathika K., et al.
Publicado: (2022)

Cost of illness of non-multidrug-resistant tuberculosis in Germany: an update
por: Diel, Roland, et al.
Publicado: (2020)

Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis
por: Skrahin, Aliaksandr, et al.
Publicado: (2016)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Costs of treating multidrug-resistant TB in California in 2022
por: Katrak, S., et al.
Publicado: (2023)

Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh
por: Rifat, Mahfuza, et al.
Publicado: (2015)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Multidrug-resistant tuberculosis
por: Lemos, Antônio Carlos Moreira, et al.
Publicado: (2013)

Outcomes of Comprehensive Care for Children Empirically Treated for Multidrug-Resistant Tuberculosis in a Setting of High HIV Prevalence
por: Satti, Hind, et al.
Publicado: (2012)

Factors related to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis in Bangladesh
por: Rifat, Mahfuza, et al.
Publicado: (2015)

Multidrug-resistant tuberculosis
por: Zager, Ellen M, et al.
Publicado: (2008)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania
por: Katale, Bugwesa Z., et al.
Publicado: (2020)

Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine
por: Aibana, Omowunmi, et al.
Publicado: (2017)

Cost-Effectiveness Comparison of Genechip and Conventional Drug Susceptibility Test for Detecting Multidrug-Resistant Tuberculosis in China
por: Pang, Yu, et al.
Publicado: (2013)

Multidrug-resistant tuberculosis in prison inmates, Azerbaijan.
por: Pfyffer, G E, et al.
Publicado: (2001)

Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru
por: Nathavitharana, Ruvandhi R., et al.
Publicado: (2017)

Characteristics of multidrug-resistant tuberculosis in Namibia
por: Ricks, Philip M, et al.
Publicado: (2012)

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis
por: Silva, Denise Rossato, et al.
Publicado: (2018)

Multidrug-resistant Tuberculosis in Central Asia
por: Cox, Helen Suzanne, et al.
Publicado: (2004)

Nomogram to predict multidrug-resistant tuberculosis
por: Wang, Saibin, et al.
Publicado: (2020)

Pharmacotherapy for multidrug resistant tuberculosis
por: Chhabra, Naveen, et al.
Publicado: (2012)

The Threat of Multidrug-resistant Tuberculosis
por: Paul, Rudrajit
Publicado: (2018)

Fistulized multidrug-resistant tuberculosis
por: El Omri, Naoual, et al.
Publicado: (2017)

Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007
por: Marks, Suzanne M., et al.
Publicado: (2014)

Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.
por: Rattan, A, et al.
Publicado: (1998)

Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain.
por: Rullán, J V, et al.
Publicado: (1996)

Prospects for Advancing Tuberculosis Control Efforts through Novel Therapies
por: Salomon, Joshua A, et al.
Publicado: (2006)

Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization
por: Eedara, Basanth Babu, et al.
Publicado: (2023)

Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen
por: Achar, Jay, et al.
Publicado: (2015)

Efficacy and effect of free treatment on multidrug-resistant tuberculosis
por: ZHANG, QING, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2ocr7hl7qoa28ok5pq9sovunlt